Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CORRECTION: Vivos Therapeutics Q3 EPS $(0.26), Same YoY, Sales $4.25M Beat $3.72M Estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.26) per share. This is unchanged from the same period last year. The company reported quarterly sales of $4.25 million which beat the analyst consensus
byBenzinga Newsdesk
December 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.26) per share. This is unchanged from the same period last year. The company reported quarterly sales of $4.25 million which beat the analyst consensus estimate of $3.72 million by 14.14 percent. This is a 6.60 percent decrease over sales of $4.55 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

A Preview Of Lantronix’s Earnings

By Benzinga Insights
August 17, 11:19 AM
  Lantronix (NASDAQ:LTRX) is set to give its latest quarterly earnings report on Thursday, 2022-08-18. Here's what investors need to know before the announcement. Analysts estimate that Lantronix will report an earnings per share (EPS) of $0.09.

LTRX